Novel Dual-Inhibitor Drugs Achieve Complete Tumor Remission in Preclinical Immunotherapy Trials

Johns Hopkins researchers develop dual HIF-1/2 inhibitors that, when paired with immunotherapy, achieve total tumor elimination and long-term immunity in mice.

By: AXL Media

Published: Apr 3, 2026, 11:14 AM EDT

Source: Information for this report was sourced from Rockefeller University Press

Targeting the Master Regulators of Malignancy

A breakthrough in oncology research has identified a potent new method for dismantling the survival mechanisms of solid tumors. By targeting Hypoxia-Inducible Factors 1 and 2 (HIF-1/2), scientists have successfully inhibited the transcription factors responsible for controlling hundreds of genes linked to cancer growth, nutrient supply, and metastasis. While previous therapies have targeted HIF-2 alone, this new class of drugs provides a dual-action approach, addressing the distinct yet complementary roles both factors play in helping cancer cells thrive in low-oxygen environments.

Accelerating Discovery via Computer-Aided Drug Design

The development of these novel compounds was made possible through a collaboration with the University of Maryland School of Pharmacy’s Computer-Aided Drug Design Center. Using a technology known as SILCS, researchers were able to predict which small molecules would bind to the crystal structure of the HIF proteins. This computational approach allowed the team to narrow their focus from millions of potential chemical compounds to just a few hundred, significantly accelerating the timeline from initial concept to a functional, "best-in-class" drug candidate.

Overcoming Immunotherapy Resistance

One of the most significant hurdles in modern oncology is the ability of tumors to suppress the immune system, rendering treatments like checkpoint inhibitors ineffective. The study found that HIF-1/2 levels, which typically rise in the oxygen-depleted centers of tumors, act as a shield against immune attacks. However, when the new dual inhibitors were administered alongside anti-PD1 or anti-CTLA-4 therapies, the combination triggered complete remission in over 50% of the subjects. Notably, these effects were seen even in tumors that had previously shown total resistance to immunotherapy alone.